Daré Bioscience soars on birth control device trial data

** Shares of women’s health firm Daré Bioscience DARE.O rise 88% to $4.72

** Stock set for best day in over 5 years, if gains hold

** Co says its medical device, Ovaprene, showed a pregnancy rate of about 9% among participants, in an ongoing late-stage study, in line with previous results

** Ovaprene is an investigational, hormone-free, monthly intravaginal device to prevent pregnancy

** An independent safety board reviewed the data and recommended the study continue without changes, co says

** Vaginal odor was the main side effect, leading 17% of participants to leave the study

** Ovaprene works by releasing a non-hormonal agent that slows sperm and uses a polymer barrier to block them from reaching the cervix

** Including session moves, stock up 50% YTD